Breaks Categories: News

FridayJan 08, 2021 11:56 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Issues Letter to Shareholders

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today issued a letter to its shareholders and the investment community from its CEO and President James Sapirstein. The letter discusses AzurRx BioPharma’s optimism and enthusiasm for 2021 and its extraordinary accomplishments in the face of so many recent challenges. “This year, already, we are building on the momentum and wasted no time in making an impact with the announcement of a transformative in-licensing agreement with First Wave Bio, bringing in a new asset and two new GI indications into our development fold,”…

Continue Reading

ThursdayJan 07, 2021 11:08 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces New VP of Broker and Consultant Partnerships

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has appointed Claudia Rimerman Kraut in the newly created role of vice president of broker and consultant partnerships. Kraut comes to her new responsibilities with impressive senior-management experience at Omada Health, American Well, AIG, United Healthcare and Humana. Kraut will lead Dario's benefit consultant and alliance outreach and be a senior member of DRIO’s employer sales team. Kraut boasts a work record with a unique and notable combination of benefits, partnerships and digital health experience, most recently serving as director of alliances at Omada Health. “We believe that Claudia's deep…

Continue Reading

ThursdayJan 07, 2021 10:44 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Biotech Showcase Digital 2021 Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be participating in the upcoming Biotech Showcase Digital 2021 conference. The multiday event is scheduled for Jan. 11–15, 2021. As part of the company’s planned participation, AzurRx president and CEO James Sapirstein, along with other members of the senior management team, will attend virtual one-on-one meetings with registered investors and pharmaceutical companies at the prestigious event. During those meetings, the AzurRx representatives will discuss AZRX’s business strategy and clinical-development programs, answer questions and note projected company milestones. To register for the event, visit https://ibn.fm/UiWoZ To view…

Continue Reading

ThursdayJan 07, 2021 10:14 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Releases Disposable Pediatric EEG Headset

Earlier this month, Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, announced that its proprietary NeuroCap(TM) would be available for pediatric patients in the United States. The company noted that the child-sized EEG headset reduces the time typically needed to measure and mark a pediatric patient’s head, as well as for post-test sanitation protocols; the company also observed that the pediatric-sized NeuroCap, designed for use with children aged 2 to 18, could be used in emergency rooms, intensive care units and clinics. A recent “Health Insider” article explained that EEG tests can be required to investigate seizures, sleep…

Continue Reading

ThursdayJan 07, 2021 9:45 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright BioConnect 2021 Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO, John Climaco, will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The event is slated to be held from Jan. 11-14, 2021, with Climaco’s presentation scheduled for 6:00 a.m. ET on the first day of the event. Interested parties should visit https://ibn.fm/09lxu to register. The webcast will be available on demand starting at 6:00 a.m. ET on Monday, Jan. 11, 2021. Replays of the presentation will be available…

Continue Reading

WednesdayJan 06, 2021 12:22 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Completes QM CoRE(TM) Integration

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”) novel active-learning Computational Research Engine (CoRE(TM)). According to the update, CoRE was integrated with Helomics’ proprietary TumorSpace(TM) knowledgebase of 150,000 tumor drug response profiles and the TruTumor(TM) patient primary tumor cell line assay. The move allows Helomics to offer a revolutionary new AI-driven patient-centric drug discovery service to pharmaceutical companies that will significantly improve the chances of successfully translating new drugs into the clinic. “With…

Continue Reading

WednesdayJan 06, 2021 10:50 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Participation in Two Upcoming Virtual Events

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, will be presenting at two investor conferences in January: the SNN Network Canada Virtual Event and the H.C. Wainwright Bioconnect 2021 Virtual Conference. Company founder and CEO Dr. Jack Regan will represent LexaGene at both events. The SNN Network Canada Virtual Event is scheduled for Thursday, Jan. 7, 2021; LexaGene’s live presentation is slated to begin at 1:30 p.m. ET. Those interested can find the webcast presentation on the conference event platform under the agenda tab following the event. The H.C. Wainwright Bioconnect…

Continue Reading

WednesdayJan 06, 2021 10:43 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in H.C. Wainwright BioConnect Virtual Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it will participate in the virtual H.C. Wainwright BioConnect Conference taking place on Jan. 11-14, 2021. According to the update, AzurRx BioPharma president and CEO James Sapirstein will take part in virtual one-on-one meetings with registered investors and pharmaceutical companies. Sapirstein will be available to provide an overview of the company’s business and clinical development programs, as well as discuss anticipated 2021 milestones. Interested parties should visit https://ibn.fm/bNYP3 to register for the event. To view the full press release, visit…

Continue Reading

WednesdayJan 06, 2021 9:31 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Upcoming H.C. Wainwright Bioconnect Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Tuesday announced that it will present at the H.C. Wainwright Bioconnect 2021 Conference. According to the update, the presentation will be available on-demand throughout the event from Jan. 11-14, 2021, starting at 6:00 a.m. ET. In addition, a webcast of the presentation will be available via the IR section of the company’s website and will be archived and accessible for at least 90 days. To view…

Continue Reading

WednesdayJan 06, 2021 8:30 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Launches Proprietary Technology for Obstructive Sleep Apnea Treatment

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea, announced its commercial launch of AireO2(TM). AireO2 is a new patient-management software technology designed to assist health-care providers to diagnose, treat and monitor patients with obstructive sleep apnea (“OSA”) and its related conditions. With an estimated 1 billion people suffering from OSA around the world, it is the most predominant diseases, and can cause life-threatening high blood pressure, heart failure, stroke and other health problems. and life-threatening diseases. “We believe that Vivos’ sleep-specific AireO2 patient…

Continue Reading